All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The preclinical results described in the publications were used to support the advancement of BRYN-NDS1C into the human clinical trial program currently underway.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 20, 2020
Details:
Proceeds to support clinical advancement of ADP101, a broad-spectrum oral biopharmaceutical candidate targeting food allergy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Treg therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lyell Immunopharma
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 06, 2020
Details:
The series A funding is to advance regulatory T cell therapy in autoimmune and degenerative diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T cells therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vida Ventures
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 13, 2020
Details:
Proceeds from the financing will be used to advance Kyverna's therapeutic strategy which combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the root cause of inflammatory disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T cells therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $587.5 million Upfront Cash: $17.5 million
Deal Type: Collaboration January 13, 2020
Details:
Kyverna will be conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option for further development and commercialization of these programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: SAb Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 07, 2020
Details:
The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
